Phase III chemoprevention trial of selenium supplementation in persons with resected stage I non-small-cell lung cancer

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 4, 2005, Pages 313-315

  Karp, Daniel D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLDEOXYURIDINE; ARACHIDONATE 5 LIPOXYGENASE; BIOLOGICAL MARKER; CARCINOGEN; CYTOSINE; DNA METHYLTRANSFERASE; SELENIUM; TRACE ELEMENT;

ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; NONHUMAN; SECOND CANCER;

EID: 25844501489     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Parker SL, Tong T, Bolden S. Cancer Statistics, 1997. CA Cancer J Clin. 1997;47:5-27.
2. Mountain CF, Lukeman JM, Hammar SP, et al. Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J Surg Oncol. 1987;35:147-156.
3. Mountain CF. A new international staging system for lung cancer. Chest. 1986;89:2255-2335.
4. Flehinger BJ, Melamed MR, Zaman MB, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering study. Am Rev Resp Dis. 1984;130:555-560.
5. Smith AR, Nigam BK, Thompson JM. Second primary lung carcinoma. Thorax. 1976;31:507-516.
6. Pairolero PC, Williams DE, Bergstralh EJ, et al. Post-surgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg. 1984;38:331-338.
7. Thomas P, Rubinstein L, and the Lung Cancer Study Group. Cancer recurrence after resection: T1N0 non-small cell lung cancer. Ann Thorac Surg. 1990;49:242-247.
8. Thompson HJ, Meeker LD, Becci PJ. Effect of combined selenium and retinyl acetate treatment on mammary carcinogenesis. Cancer Res. 1981;41:1413-1416.
9. Thompson HJ, Becci PJ. Selenium inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis in the rat. J Natl Cancer Inst. 1980;65:1299-1301.
10. Harr JR, Whanger PD. Effect of dietary selenium on N-2 fluorenyl-acetamide (FAA)-induced cancer in vitamin E supplemented, selenium depleted rats. Clin Toxicol. 1972;5:187-194.
11. Jacobs M. Effects of selenium on chemical carcinogens. Prev Med. 1980;9:362-367.
12. Schrauzer GN, Ishmael D. Effects of selenium and of arsenic on the genesis of spontaneous mammary tumors in inbred C3H mice. Ann Clin Lab Sci. 1974;4:441-447.
13. Greeder GA, Milner JA. Factors influencing the inhibitory effect of selenium on mice inoculated with Ehrlich ascites tumor cells. Science. 1980;209:825-827.
14. Griffin AC. Role of selenium in the chemoprevention of cancer. Adv Cancer Res. 1979;29:419-442.
15. Daoud AC, Griffin AC. Effects of selenium and retinoic acid on the metabolism of N-acetyl aminofluorene and N-hydroxyacetylaminofluorene. Cancer Lett. 1978;5:231-237.
16. Marshall MV, Rasco MA, Griffin AC. Effects of selenium on benzo (a) pyrene metabolism. Fed Proc. 1978;37:1383.
17. Peretz A, Nève J, Desmedt J, et al. Lymphocyte response is enhanced by supplementation of elderly subjects with selenium-enriched yeast. Am J Clin Nutr. 1991;53:1323-1328.
18. Willer WC, Morris JS, Pressel S, et al. Prediagnostic serum selenium and risk of cancer. Lancet 1983;2:130-134.
19. Salonen JT, Alfthan G, Huttunen JK, et al. Association between serum selenium and the risk of cancer. Am J Epidemiol. 1984;120:342-349.
20. Schrauzer GN, White DA, Schneider CJ. Cancer mortality correlation studies, III. Bioinorganic Chem. 1977;7:23-34.
21. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and diseases-specific mortality in the general poputation. J Natl Cancer Inst. 1993;85:1483-1492.
22. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA. 1996;276:1957-1963.
23. Avis IM, Jett M, Boyle T, et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest. 1996;97:806-813.
24. Kulkarni AP, Cai Y, Richards IS. Rat pulmonary lipoxygenase: Dioxygenase activity and role in xenobiotic metabolism. Int J Biochem. 1992;24:255-261.
25. Moody TR, Leyton J, Martinez A, et al. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res. 1998;24:617-628.
26. Rioux N, Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis. 1998;19:1393-1400.
27. Klein E. Opportunities for prevention of prostate cancer: genetics, chemoprevention, and dietary intervention. Rev Urol. 2002;4(suppl 5):S18-S28.
28. Fiala ES, Staretz ME, Pandya GA, et al. Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined by an improved assay for cytosine methyltransferase and DNA cytosine methylation. Carcinogenesis. 1998;19:597-604.
29. Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small cell lung cancer. J Natl Cancer Inst. 2000;92:1511-1516.
30. Belinsky SA, Nikula KJ, Palmisano WP, et al. Aberrant methylation of p161NK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998;95:11891-11896.
31. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter hypermethylation in sputum. Cancer Res. 2000;60:5954-5958.
32. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999;59:67-70.